Rapamycin inhibits re-endothelialization after percutaneous coronary intervention: By impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells

Texas Heart Institute Journal

Volumn 37, Issue 2, 2010, Pages 194-201

  Liu, Hai Tao ^a   Li, Fei ^a   Wang, Wen Yong ^b   Li, Xiao Jing ^b   Liu, Yi Meng ^a   Wang, Rui An ^b   Guo, Wen Yi ^a   Wang, Hai Chang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Animals; Apoptosis drug effects; Cell proliferation drug effects; Coronary artery disease prevention control therapy; Dose response relationship, drug; Endothelial cells drug effects immunology pathology; Endothelium, vascular cytology physiopathology; Platelet aggregation inhibitors therapeutic use; Sirolimus pharmacology therapeutic use; Stents; Vascular endothelial growth factors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN; VASCULOTROPIN; CARDIOVASCULAR AGENT; METAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BARE METAL STENT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG MECHANISM; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; IN-STENT RESTENOSIS; MALE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; RAT; STEM CELL; ANIMAL; CELL CULTURE; CELL MOTION; DRUG EFFECT; INSTRUMENTATION; METABOLISM; PATHOLOGY; PROSTHESIS; SPRAGUE DAWLEY RAT; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; APOPTOSIS; CARDIOVASCULAR AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; MALE; METALS; MODELS, ANIMAL; PROSTHESIS DESIGN; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; STEM CELLS; STENTS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954934963     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/ Ilia blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000;343 (6):385-391.
2. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Gi-ambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999;341(26):1949-1956.
3. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/ IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341(5):319-327.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331(8):496-501.
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331(8):489-495.
6. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revasculariza-tion. N Engl J Med 2002;346(23):1773-1780.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.N Engl J Med 2003;349(14):1315-1323.
8. Williams DO, Abbott JD, Kip KE; DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006;114(20):2154-2162.
9. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364 (9434):583-591.
10. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 2004;5(1):9-15.
11. Eisenberg MJ. Drug-eluting stents: some bare facts. Lancet 2004;364(9444):1466-7.
12. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data) Am J Cardiol 2005;95(12):1469-1472.
13. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rod-riguez-Alemparte M, Berrocal D, et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006;47(1):205-207.
14. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364 (9444):1519-1521.
15. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115(11):1440-1455.
16. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005;45(6):941-946.
17. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115(8):1051-1058.
18. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293(17):2126-21230.
19. Park DW, Park SW, Lee SW, Kim YH, Lee CW, Hong MK, et al. Frequency of coronary arterial late angiographic stent thrombosis (LAST) in the first six months: outcomes with drug-eluting stents versus bare metal stents. Am J Cardiol 2007;99(6):774-778.
20. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation 2003;108(1):2-5.
21. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adel-man S, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99(16):2164-2170.
22. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994;91(26):12574-12578.
23. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270(2):815-822.
24. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369 (6483):756-758.
25. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991;23(1 Pt 1): 521-524.
26. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994;14(1):1-22.
27. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996;58(5):373-395.
28. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2(8656):227.
29. Blazquez-Domingo M, Grech G, von Lindern M. Translation initiation factor 4E inhibits differentiation of erythroid progenitors. Mol Cell Biol 2005;25(19):8496-506.
30. Rukshin V, Shah PK, Cercek B, Finkelstein A, Tsang V, Kaul S. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. Circulation 2002;105(16):1970-1975.
31. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, et al. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998;97(6):581-588.
32. Yin T, Ma X, Zhao L, Cheng K, Wang H. Angiotensin II promotes NO production, inhibits apoptosis and enhances adhesion potential of bone marrow-derived endothelial progenitor cells. Cell Res 2008;18(7):792-799.
33. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Distribution of sirolimus in rat tissue. Clin Biochem 1997;30(2):135-142.
34. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005;46(2):454-460.
35. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9(6):702-712.
36. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmer-ling P, Luscher TF, Tanner FC. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112(13):2002-2011.
37. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10(6):1366-1380.
38. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, et al. Twenty-eight-day efficacy and pharmacokinetics [sic] of the sirolimus-eluting stent. Coron Artery Dis 2002;13(3):183-188.
39. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilen-sky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104(10):1188-1193.
40. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardio-vasc Res 2004;63(4):617-624.
41. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106(18):2379-2384.
42. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acam- pado E, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106(10):1195-1198.
43. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006;48(8):1538-1547.
44. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998;81(7A):14E-17E.
45. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48 (1):193-202.
46. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76(3):412-417.
47. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration.J Clin Invest 1996;98(10):2277-2283.
48. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-135.
49. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006;48(6):286-292.
50. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Drug-eluting stents: sirolimus and pa-clitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 2005;524(1-3):19-29.
51. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108(21):2710-2715.
52. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006;98(11):1405-1413.
53. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, Fiedler W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004;300(1):65-71.
54. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 2006;39(2):117-125.
55. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 2007;115(5):553-561.
56. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascu-larization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18(14):3964-3972.
57. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphati-dylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541-1545.
58. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111(Pt 24): 3621-3631.